Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia

NCT05192304 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: TPN-672

Sponsor

Jiangsu Kanion Pharmaceutical Co., Ltd

Collaborators

[object Object]